Denali Therapeutics (DNLI) Total Debt (2022)

Denali Therapeutics (DNLI) posted quarterly Total Debt of $4.4 million for Q4 2022, up 204.09% quarter-over-quarter from $1.4 million in Q3 2022.

Denali Therapeutics (DNLI) Total Debt (2022) Analysis & Trends

Denali Therapeutics (DNLI) has reported Total Debt for 1 consecutive years, with $4.4 million the latest figure, recorded in Q4 2022.

In Q4 2022, Total Debt changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2022 stood at $4.4 million (changed N/A YoY), while the FY2022 annual figure was $4.4 million, changed N/A from the prior year.
Total Debt grew to $4.4 million in Q4 2022 per DNLI's latest filing, from $1.4 million in the prior quarter.
Across five years, Total Debt topped out at $4.4 million in Q4 2022 and bottomed at $1.4 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Denali Therapeutics	3.90 Bn	3.90 Bn	3.51 Mn	-

Download Data